Exatecan Mesylate in Treating Children With Relapsed or Refractory Rhabdomyosarcoma

ClinicalTrials.gov ID: NCT00055939

Public ClinicalTrials.gov record NCT00055939. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 15, 2026, 10:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II Study Of Intravenous DX-8951f (EXATECAN MESYLATE) Administered Daily For Five Days Every Three Weeks To Pediatric Patients With Relapsed Or Refractory Rhabdomyosarcoma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of exatecan mesylate in treating children who have relapsed or refractory rhabdomyosarcoma.

Study identification

NCT ID: NCT00055939
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Daiichi Sankyo; Industry
Enrollment: Not listed

Conditions and interventions

Conditions

Sarcoma

Interventions

exatecan mesylate Drug

Drug

Eligibility (public fields only)

Age range: Not listed
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Dec 31, 2002
Primary completion: Mar 31, 2006
Completion: Mar 31, 2006
Last update posted: May 15, 2012

2003 – 2006

United States locations

U.S. sites: 8
U.S. states: 6
U.S. cities: 7

Facility	City	State	ZIP	Site status
University of Colorado Cancer Center at University of Colorado Health Sciences Center	Denver	Colorado	80218	—
Nemours Children's Clinic	Jacksonville	Florida	32207	—
Cancer Institute of New Jersey	New Brunswick	New Jersey	08903	—
Memorial Sloan-Kettering Cancer Center	New York	New York	10021	—
St. Jude Children's Research Hospital	Memphis	Tennessee	38105	—
Medical City Dallas Hospital	Dallas	Texas	75230	—
Simmons Cancer Center at University of Texas Southwestern Medical Center - Dallas	Dallas	Texas	75390-9063	—
University of Texas - MD Anderson Cancer Center	Houston	Texas	77030-4009	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00055939, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted May 15, 2012 · Synced Sep 15, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00055939 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →